Approximately half of the PTCs (43.8%, 21/48) exhibited a high SLC34A2 protein expression in tumor tissue compared with the adjacent normal thyroid tissue; 90.5% (19/21), 76.2% (16/21), and 76.2% (16/21) of these PTCs with high SLC34A2 exhibited capsular invasion, extra-thyroid metastasis, and high UIC, respectively; the percentage was dramatically higher than that of the unchanged SLC34A2 expression group [54.5% (12/22), 40.9% (9/22), and 31.8% (7/22), P all < 0.05]. This evidence concerns the gene SLC34A2 and neoplasm.